- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.10. | CHOSA ONCOLOGY AB: CHOSA's presented data on the carboplatin response predictor in breast cancer patients on the ESMO conference | 1 | Cision News | ||
| 07.10. | CHOSA ONCOLOGY AB: CHOSA Wins 2025 Jiangning International Entrepreneurship Contest (Greater Shanghai region), China | 1 | Cision News | ||
| CHOSA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 30.09. | CHOSA ONCOLOGY AB: CHOSA announces positive results from a clinical study in collaboration with ETOP/EORTC on platinum predictor in lung cancer | 2 | Cision News | ||
| 08.08. | CHOSA ONCOLOGY AB: CHOSA's presents data on the carboplatin response predictor in breast cancer patients on the annual ESMO conference | 2 | Cision News | ||
| 01.08. | Spotlight Stock Market: Market Notice 145/25 - Information regarding CHOSA Oncology AB's subscription option | 2 | Cision News | ||
| 01.08. | CHOSA ONCOLOGY AB: Chosa Oncology's warrants of series TO 2 to be admitted to trading | 1 | Cision News | ||
| 01.08. | Spotlight Stock Market: Market Notice 144/25 - Last day of trading in CHOSA Oncology AB's BTU | 2 | Cision News | ||
| 31.07. | CHOSA ONCOLOGY AB: Chosa Oncology announces the last day of trading in BTU | 1 | Cision News | ||
| 31.07. | Spotlight Stock Market: Market Notice 143/25 - Trading halt in CHOSA Oncology AB's BTU | 1 | Cision News | ||
| 01.07. | CHOSA ONCOLOGY AB: CHOSA extends the timeline for biopsy collection prior to publication from the SPLENDOUR study | 1 | Cision News | ||
| 27.06. | CHOSA ONCOLOGY AB: Chosa Oncology announces outcome in rights issue | 2 | Cision News | ||
| 25.06. | CHOSA ONCOLOGY AB: Last subscription day in Chosa's subscription period | 2 | Cision News | ||
| 25.06. | CHOSA ONCOLOGY AB: CHOSA files new patent application to predict which patients may benefit from platinum chemotherapy and immunotherapy | 5 | Cision News | ||
| 13.06. | Bulletin from the annual general meeting on 13 June 2025 in Chosa Oncology AB | 1 | Cision News | ||
| 12.06. | The subscription period in Chosa Oncology AB's rights issue begins today - the company invites to a webcast presentation | 2 | Cision News | ||
| 10.06. | Chosa Oncology AB publishes information document in connection with rights issue of units | 2 | Cision News | ||
| 09.06. | CHOSA ONCOLOGY AB: CHOSA Oncology invites investors to two upcoming presentations | 1 | Cision News | ||
| 06.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.06.2025 | 368 | Xetra Newsboard | Das Instrument 37P FR0010341032 FONCIERE INEA SA EO 14,39 EQUITY wird cum Kapitalmassnahme gehandelt am 06.06.2025 und ex Kapitalmassnahme am 09.06.2025 The instrument 37P FR0010341032 FONCIERE INEA... ► Artikel lesen | |
| 03.06. | Spotlight Stock Market: Market Notice 101/25 - Information regarding the rights issue from CHOSA Oncology AB | 3 | Cision News | ||
| 02.06. | Chosa Oncology AB resolves on a directed issue of units and on a rights issue of units to provide funds for reaching several value-enhancing milestones | 3 | Cision News |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,68 | -0,04 % | Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen | DJ Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen
Von Dylan Tokar und Peter Loftus
DOW JONES--Novartis will den US-Biotech-Konzern Avidity Biosciences für 12 Milliarden... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 24,920 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| INTENSITY THERAPEUTICS | 1,310 | 0,00 % | Intensity Therapeutics stock soars after phase 1/2 data publication | ||
| QIAGEN | 40,395 | -1,43 % | QIAGEN N.V.: QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025 | New EZ2 DNA Investigator Sep&Prep Kit automates sexual assault sample processing, improving sperm DNA recovery and separation from victim DNA Workflow on EZ2 Connect Fx delivers high-quality... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 28,900 | -1,30 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
| ARVINAS | 9,930 | 0,00 % | Arvinas stock price target raised to $14 from $10 at BTIG on KRASG12D degrader potential | ||
| IMMUNOVANT | 24,810 | +14,38 % | Immunovant gains amid takeover speculation | ||
| BIONTECH | 90,05 | -0,39 % | Innovation trifft Biotech: Dieses Unternehmen mischt Big Pharma mit smarter Wirkstoff-Revolution auf! | Anzeige / WerbungEine spannende Alternative zu Evotec, BioNTech und Co. ist BioNxt Solutions.
Das kanadisch-deutsche Unternehmen unterscheidet sich mit seinem Geschäftsmodell erfrischend... ► Artikel lesen | |
| EVOTEC | 7,096 | -0,76 % | BB Biotech & Evotec: Biotech immer noch historisch "billig"? Und die bessere Aktie ist? | BB Biotech & Evotec: Zwei Aktien, die ein klar unterschiedliches Risikopotential bieten. Deshalb die Frage: Wird höheres Risiko durch höhere Gewinnchncen ausgeglichen? Ein Aktienvergleich für Anleger... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,910 | -2,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome | The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic... ► Artikel lesen | |
| MODERNA | 23,885 | +11,38 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 53,50 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,630 | 0,00 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| NUVALENT | 97,95 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results | Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC
On track to report topline pivotal data for neladalkib in TKI... ► Artikel lesen | |
| HARVARD BIOSCIENCE | 0,570 | -2,56 % | Harvard Bioscience, Inc.: Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States | HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), a leading provider of innovative laboratory equipment, is pleased... ► Artikel lesen |
Das Unternehmen CHOSA ONCOLOGY AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,009 (+9,57 %) liegt der Kurs bei 0,103 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHOSA ONCOLOGY AB finden Sie auf Wallstreet Online.